2003
DOI: 10.1182/blood-2003-01-0139
|View full text |Cite
|
Sign up to set email alerts
|

Proliferation kinetics of subpopulations of human marrow cells determined by quantifying in vivo incorporation of [2H2]-glucose into DNA of S-phase cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2005
2005
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(17 citation statements)
references
References 25 publications
0
17
0
Order By: Relevance
“…Our results show that CD133+ cells were located predominantly in layer III of the human SVZ, and within the central region of layer I-III in the RMS. Although the function of CD133 is uncertain, it is often considered to be a multipotent 'stem cell' marker, and is expressed in carcinogenic stem cells (Pilkington, 2005;Song et al, 2008), human embryonic stem cells (Barraud et al, 2007;Uchida et al, 2000) and haematopoetic progenitor cells (Schwartz et al, 2003;Wagner et al, 2004). The expression of CD133+ cells throughout the RMS, together with its co-expression with PCNA, supports the notion that these cells may be stem or progenitor cells distributed throughout the extent of the human RMS.…”
Section: Discussionmentioning
confidence: 78%
“…Our results show that CD133+ cells were located predominantly in layer III of the human SVZ, and within the central region of layer I-III in the RMS. Although the function of CD133 is uncertain, it is often considered to be a multipotent 'stem cell' marker, and is expressed in carcinogenic stem cells (Pilkington, 2005;Song et al, 2008), human embryonic stem cells (Barraud et al, 2007;Uchida et al, 2000) and haematopoetic progenitor cells (Schwartz et al, 2003;Wagner et al, 2004). The expression of CD133+ cells throughout the RMS, together with its co-expression with PCNA, supports the notion that these cells may be stem or progenitor cells distributed throughout the extent of the human RMS.…”
Section: Discussionmentioning
confidence: 78%
“…Sim- plete loss of function in the PU.1/CEBPA/RUNX1 circuit, since experimentally, complete inactivation of PU.1, CEBPA, or RUNX1 kills AML cells, even as partial loss of function of any one of these is leukemogenic (17,43,(68)(69)(70)(71)(72); and accordingly, NPM1, RUNX1, and biallelic CEBPA mutations, though highly recurrent in AML, are mutually exclusive (37)(38)(39). PU.1, CEBPA, and RUNX1 have been shown to promote exponential replication kinetics by binding to MYC enhancers to produce high-grade activation of MYC (the master transcription factor coordinator of cell proliferation) and by co-binding with MYC at its target genes (73)(74)(75)(76)(77)(78)(79)(80)(81)(82). This contrasts with the quiescence imposed by stem cell master transcription factors such as HLF in HSCs (73)(74)(75)(76)(77)(78)(79)(80)(81)(82).…”
Section: Resistance In Vivo and In Vitro Was By Avoidance Of Pharmacomentioning
confidence: 99%
“…PU.1, CEBPA, and RUNX1 have been shown to promote exponential replication kinetics by binding to MYC enhancers to produce high-grade activation of MYC (the master transcription factor coordinator of cell proliferation) and by co-binding with MYC at its target genes (73)(74)(75)(76)(77)(78)(79)(80)(81)(82). This contrasts with the quiescence imposed by stem cell master transcription factors such as HLF in HSCs (73)(74)(75)(76)(77)(78)(79)(80)(81)(82). In computational analyses, such skewing of intrinsic replication rates logarithmically favors decoupling replication from forward differentiation in lineage progenitors as the most efficient strategy for malignant transformation (83).…”
Section: Resistance In Vivo and In Vitro Was By Avoidance Of Pharmacomentioning
confidence: 99%
“…To measure the turnover of DNA [1,2] or cells [3][4][5] in various tissues, DNA can be labeled with isotope-labeled precursor. In such studies, the DNA is extracted, hydrolyzed, and analyzed to determine label incorporation by mass spectrometry.…”
Section: Introductionmentioning
confidence: 99%